Summit Therapeutics Inc. (SMMT) Stock Price & How to Invest

Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 and VEGF simultaneously. Summit in-licensed ivonescimab from China's Akeso in January 2023 and holds rights to develop and commercialize it across North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso keeps China and certain other regions. The lead opportunity is non-small cell lung cancer (NSCLC), where Phase III data have shown ivonescimab extending progression-free survival versus Merck's Keytruda (pembrolizumab), plus additional programs in colorectal and other cancers. The company generates no meaningful product revenue yet and funds operations from its cash balance while running large global trials.

The investment picture is that of a high-risk, high-reward binary biotech. Summit's roughly $12 billion market value (July 2026) rests on expectations for ivonescimab rather than on sales or profits, so the stock is driven by catalysts: the FDA has accepted a Biologics License Application with a target decision (PDUFA) date of November 14, 2026, and multiple Phase III readouts (HARMONi-3, HARMONi-7) are due in 2027. Positive data or approval could unlock a large commercial market against a Keytruda franchise worth tens of billions, but a single trial miss, a regulatory setback, or the need to raise more cash could sharply cut the value. This is a speculative, event-driven holding, not an income or earnings stock.

Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. With ongoing cash burn and no product sales, Summit may need to raise capital, diluting shareholders, and its stock is highly volatile and prone to large single-day moves around catalysts.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Summit Therapeutics Inc.'s investor relations page or your broker.

• Product revenue (TTM): ~$0 (pre-commercial)
• Cash & short-term investments (Q1 2026): ~$598.7 million
• Quarterly operating cash burn (Q1 2026): ~$122.3 million
• Market cap: ~$12 billion
• Share price: ~$15
• Shares outstanding: ~776 million
• Lead-drug FDA decision (PDUFA): ~November 14, 2026

As a clinical-stage biotech with no meaningful product sales, Summit cannot be valued on earnings or a P/E ratio; its roughly $12 billion market value (July 2026) reflects expectations for ivonescimab rather than current financials. Standard metrics like revenue and profit are near zero, so investors weigh trial data, the market size of NSCLC, and cash runway instead. Valuation is therefore speculative and can move dramatically on a single readout or regulatory event.

There are three common ways to get SMMT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SMMT sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SMMT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Summit Therapeutics is a clinical-stage biotech that trades as a bet on one drug, ivonescimab, so its outcome hinges on trial data and FDA decisions rather than current revenue. It behaves like a binary, catalyst-driven stock: large moves around readouts and approvals, no earnings to anchor valuation, and real risk of failure alongside significant upside if the drug succeeds.

Whether SMMT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SMMT a buy?, and where the stock could go from here in the SMMT stock forecast.

For income investors, whether SMMT pays a dividend and how the payout looks is covered in does SMMT pay a dividend?